TBCRC 047: InCITe (Breast Cancer)

We are doing this study to find out if avelumab is a safe and effective option for triple negative metastatic breast cancer when it is combined with different anti-cancer drugs.

Metastatic Triple Negative Breast Cancer

Adults ages 18+ who:

• Are diagnosed with metastatic triple negative breast cancer
• Have received no more than 2 lines of previous treatment for their cancer
• Have never been treated with sacituzumab govitecan
• Have not used more than one immunotherapy drug for their cancer

For more information about who can join this study, please contact the study team at 919-660-1278.

If you choose to join this study you will:

• Get a random assignment (fair, equal chance) to 1 of 3 groups
• One group will receive avelumab and liposomal doxorubicin
• One group will receive avelumab, liposomal doxorubicin, and binimetinib
• One group will receive avelumab with sacituzumab govitecan
• Have blood draws
• Have imaging scans
• Have heart scans (EKG and echocardiogram)
• Have biopsies
• Give us permission to store your tissue samples
• Answer questionnaires

After you finish your study regimen, we will call you every 3 months for 1 year to see how you are doing.